APAC Autoinjectors Market

APAC Autoinjectors Market Size (2022 to 2027)

The Asia Pacific Autoinjectors Market size is estimated to grow from USD 0.52 billion in 2022 to USD 1.20 billion by 2027, registering a CAGR of 18.2% during the forecast period.

The rising prevalence of targeted therapies, the rising incidence of anaphylaxis, the rising preference for self-administration of drugs, favorable reimbursements, and government support, usability benefits, the growing number of regulatory approvals, the availability of generic versions of autoinjectors, and technological advancements are some of the significant factors promoting Asia pacific autoinjectors market growth. Autoinjectors are favored over traditional devices because they allow for more efficient and better medication administration and the development of novel formulations. In addition, product technological advances are expected to drive growth to the market. Autoinjectors provide several benefits, including lowering the risk of needle-related anxiety conditions, reducing needle-stick accidents, preserving dosage quality precision, and enhancing effectiveness. As a result of these benefits, the use of the Asia pacific autoinjectors market is accelerating.

The removal force of the safety cap, needle activation force, override force, ejection dosage, needle length, ejection time, dose setting, and auditory click detection are all factors examined while improving autoinjectors. Autoinjector use is projected to increase in the future years as a result of such technical developments. Autoinjectors are being developed to enable higher viscosity and drug concentrations to minimize medication administration frequency and improve adherence to approved treatment regimens. In the current COVID-19 environment, these elements provide an opportunity for the autoinjector industry to develop. The benefits of usability are fueling the Asia Pacific market, the rising number of regulatory approvals, and the availability of standard versions of autoinjectors, as well as favorable settlements relating to autoinjectors. Furthermore, government initiatives and technology developments are expected to make this market more advantageous. Biologics' patent expiration is expected to open up new growth opportunities for the market. The transition from biologics to biosimilars administered by autoinjectors is expected to provide lower-cost choices for individuals seeking long-term therapy. These factors are likely to present market participants with lucrative opportunities.

However, the availability of alternatives such as continuous glucose monitoring devices may hinder market growth in this region over the forecast period. In addition, auto-injectors are less painful than syringes, which boosts their popularity. The availability of alternatives such as oral pills, on the other hand, may stifle innovation. Higher injector pricing, a lack of self-injection practices in this nation, and the availability of replacement goods are all factors limiting the Asia pacific auto-injectors market's development.

This research report on the APAC Autoinjectors market has been segmented & sub-segmented the market into the following categories:

By Product:  

• Fillable Autoinjectors
• Prefilled Autoinjectors

By Usability: 

• Disposable Autoinjectors
• Reusable Autoinjectors

By Manufacturing Design: 

• Standardized Autoinjectors
• Customized Autoinjectors

By Technology: 

• Automated Autoinjectors
• Manual Autoinjectors

By Application: 

• Anaphylaxis
• Multiple Sclerosis
• Rheumatoid Arthritis

By Country: 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Regionally, Asia-Pacific is growing fastest due to the rising population, chronic diseases, and emerging economies like China and India. The high diabetic population and rising healthcare expenditures in the Asia Pacific are driving market growth, attracting several prominent autoinjector device manufacturers to the area. These firms are expanding their presence in the Asia Pacific market in various ways, including opening sales offices and forming partnerships with local pharmaceutical companies.

Due to the rising prevalence of diabetes and anaphylaxis due to food allergies in countries such as India, China, Japan, Singapore, and Australia, Asia Pacific is expected to expand at the quickest CAGR. The rising prevalence of type 1 diabetes is expected to fuel market expansion. In addition, the demand in this region is expanding due to the region's growing elderly population, which has led to an increase in the incidence of illnesses, including diabetes and cancer.

On the other hand, the market is being pushed by improved healthcare infrastructure, which is being supported by increasing technological advancements in this field. During the forecast period, Asia Pacific is anticipated to have the quickest revenue growth rate compared to other regional markets in the worldwide market.

During the forecast period, the Indian autoinjectors market is predicted to be growing at the fastest CAGR among all the APAC countries.

KEY MARKET PLAYERS:

A few of the noteworthy companies operating in the APAC Autoinjectors market profiled in this report are Mylan N.V., Pfizer, Inc., Bayer AG, Becton, Dickinson and Company, Novartis AG, Biogen Idec, Inc., Janssen North America Services, LLC, Sanofi, Unilife Corporation and Eli Lilly.